Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Mtech Access

Website
Email
01869 222 490

At Mtech Access, our goal is to ensure that medical technologies are available to the patients who need them, whilst meeting the needs of the healthcare environment.

We work in expert-led partnerships with innovators across the healthcare sector providing commercialisation strategy, evidence synthesis and analysis, and value demonstration services, supporting the journey from R&D to market.

Our services support global teams and affiliates throught the product lifescycle, across all evidence and access hurdles. We can help you with:

  • Demonstration of economic value
  • Generation of a robust evidence base
  • Optimisation of global strategy and tactics
  • Value proposition and story development
  • Deep understanding of local landscapes and stakeholders
  • Successful national reimbursement
  • Impactful local engagement and account management

Learn more

Mtech Access Ltd, 30 Murdock Road, Bicester, Oxfordshire, OX26 4PP, United Kingdom

Our areas of expertise include:

Mtech Access are exhibiting at ISPOR in the US

After many years attending ISPOR Europe, Mtech Access are excited to be attending the Global ISPOR conference May 5-8. Mtech Access are inviting ISPOR delegates to come by stand 125...

Market access and reimbursement in Canada – changes at CADTH

What do you need to know about the market access and reimbursement landscape in Canada? What changes can we expect at the Canadian Agency for Drugs and Technologies in Health...

Rare disease market access – Launching orphan drugs in secondary markets: the Nordic and MENA regions

Join us live at 1.00pm (GMT)/2.00pm (CET)/8.00am (EST) on Thursday 29th February, to explore rare disease market access challenges and learn more about these high potential markets.

How does funding flow in NHSE Regions? – Live Webinar

On Friday 23rd February at 2.00pm, we will sit down with guest speaker Richard Smale (Interim Director of System Co-ordination, NHS England [NHSE] – South West) for an all-encompassing discussion...

So, what is happening with specialised commissioning in the NHS?

Specialised commissioning continues to be an issue of significance and uncertainty for both the NHS and industry. What do the latest reports of regional push back on the plans for...

Mtech Access certified as a NICE META tool facilitating organisation

Mtech Access are now a certified NICE META Tool facilitating organisation, with three experts having passed the NICE assessment

ALL PRESS RELEASES

What role does ICER play in US market access?

The Institute for Clinical and Economic Review (ICER) is becoming an increasingly important player in US market access. As more transformative, but costly, treatments come to market, payers must continue...

Top 10 HEOR trends – A detailed look at ISPOR’s 2024–2025 topics

Specialists from across Mtech Access to look at each of ISPOR’s top 10 HEOR trends for 2024–2025. Jump in as the Mtech Access experts give their hot take on each...

The pitfalls of cutting costs on systematic literature reviews: 11 common issues to avoid

Embarking on a systematic literature review is a critical step in evidence synthesis, providing a foundation for robust decision-making in the healthcare landscape. As with most things, there are ways...

Digital options to enhance your local market access materials

How can a digital approach enhance local customer communication, particularly when tools are adapted from existing global materials? What are the options? How can we build in efficiencies whilst meeting...

EU Joint Clinical Assessment (JCA) – implications for Pharma and Medtech

Maria Dimitrova (Consultant – HTA) and Samantha Gillard (Director – HTA) provide an overview of the EU Joint Clinical Assessment (JCA) and what it means for Pharma and Medical Device...

Market access and reimbursement in key European markets

An introductory guide to European market access and reimbursement stakeholders and processes in France, Great Britain, Germany, Italy and Spain.

ALL WHITE PAPERS

Hannah Palin

Hannah Palin
Associate Director - Market Access
info@mtechaccess.co.uk
Linkedin Profile

Ewan Bennett

Ewan Bennett
Associate Director – Global Market Access
info@mtechaccess.co.uk
Linkedin Profile

Shona Lang

Shona Lang
Associate Director - Systematic Review
info@mtechaccess.co.uk
Linkedin Profile

Jodie Worrall

Jodie Worrall
Associate Director – Systematic Review
info@mtechacccess.co.uk
Linkedin Profile

Jennie Smith

Jennie Smith
Director - NHS Insight & Interaction
info@mtechaccess.co.uk
Linkedin Profile

Clare Foy

Clare Foy
Director - Global Market Access
info@mtechaccess.co.uk
Linkedin Profile

Samantha Gillard

Samantha Gillard
Director - HTA
info@mtechaccess.co.uk
Linkedin Profile

Andy Buckland

Andy Buckland
Director - Medical Writing
info@mtechaccess.co.uk
Linkedin Profile

Lydia Crowe

Lydia Crowe
Director - Commercial
info@mtechaccess.co.uk
Linkedin Profile

Prof Phil Richardson

Prof Phil Richardson
Chair & Chief Innovation Officer
info@mtechaccess.co.uk
Linkedin Profile

Andrew Spencer

Andrew Spencer
Director - Digital
info@mtechaccess.co.uk
Linkedin Profile

Anthony Bentley

Anthony Bentley
Director - Health Economics
info@mtechaccess.co.uk
Linkedin Profile

Adam Brown

Adam Brown
Director - Market Access
info@mtechaccess.co.uk
Linkedin Profile

David Niziol

David Niziol
Founder & MD
info@mtechaccess.co.uk
Linkedin Profile

Our clients include top-20 Pharmaceutical and Medical Device companies, as well as smaller specialist biopharma and medtech companies. We have extensive experience across a wide range of disease areas and products.

We also work directly with healthcare systems and health charities. For example we recently worked with Medical Detection Dogs, developing a health economic model to demonstrate the value their Medical Alert Assistance Dogs deliver for patients and healthcare systems. Read their story here.

Please contact us on info@mtechaccess.co.uk for more information about our clients.

It’s been a pleasure working with the Mtech Access dream team! Great outcomes achieved in our SMC appraisals and in a speedy fashion too! This is a massive achievement and almost unexpected, as less than 20% of Detailed Advice Documents (DADs) are positive, especially considering the complexity of this appraisal.” –  HTA Manager, top 20 Pharma

“[Mtech Access were] fantastic to work with [and] went over and above the standards expected” – Head of Market Access who commissioned a suite of UK HTA submissions

“The project absolutely met its aims and is gaining traction in the field where I already have reports that it has helped with interactions and positively increased sales” – Pharma Value & Access Manager who commissioned an Mtech Access local payer communication tool

“Mtech Access is the best consultancy, in my opinion, due to the calibre of the people. The team were really easy to work with, were quick to action everything, and kept us updated on the whole process” – Senior Market Access and Reimbursement Manager – Medtech Company

“The mock meeting was excellent and very well delivered. The team were so responsive, easy to communicate with, very flexible and able to implement things last minute. We would definitely do this again with Mtech!” – HTA & Access Lead – top 20 Pharma company

“Without Mtech Access we may have missed several deadlines, as we had multiple HTA submissions to coordinate and faced added disruption to timelines and processes due to the pandemic. The situation was challenging, and I don’t think we could have got through the process without the quality of the work, the complete understanding of the process, and fantastic project management delivered by Mtech Access.” – Head of Market Access, UK & Ireland – Pharma company

“In my experience, the team at Mtech Access are among the best in the industry. It’s always a pleasure working with them as they are appreciative of their customers’ needs, ensure timely communication, and develop payer communication tools of utmost quality in line with my expectations.” – HEOR Manager – top 20 Pharma company

“I just want to say that the payer research project was really great. I understood it was a challenge but the team did an amazing job.” – HEOR Lead – Global Market Access – top 20 Pharma company

“The HTA strategy and gap analysis from Mtech Access was highly satisfying and exceeded all expectations. We were impressed by how comprehensive the research was, and how dedicated the team were. The project management and communication from the team was perfect. 10/10.” – Senior Market Access and Public Affairs Manager – top 20 Pharma company

“The UK Diagnostic Landscape Study has proved to be really good value for money – we’re really pleased. The report has provided our UK team with a lot more detail than we had before, and we are taking learnings forward to apply to our European strategy.” – Market Access and HEOR Director – Diagnostics and Medical Device company

“I was really pleased with how the advisory board went. The outcomes were good and useful. If you are looking for something slightly different, go to Mtech. [When working with Mtech,] we know we’re going to get what’s promised and that there will always be delegates with interesting roles who have a real desire to engage in the process.” –  Market Access Manager – top 20 Pharma company

“Honestly, the best agency I have ever worked with. It felt like we were working with a partner and not an agency!” –  Global Medical Director – top 20 Pharma company

See more testimonials here

Discover more client stories and examples of our work here

Company Details

- PMLiVE

Email
Website

 Latest Content from  Mtech Access 

What role does ICER play in US market access?

The Institute for Clinical and Economic Review (ICER) is becoming an increasingly important player in US market access. As more transformative, but costly, treatments come to market, payers must continue...

Mtech Access are exhibiting at ISPOR in the US

After many years attending ISPOR Europe, Mtech Access are excited to be attending the Global ISPOR conference May 5-8. Mtech Access are inviting ISPOR delegates to come by stand 125...

Market access and reimbursement in Canada – changes at CADTH

What do you need to know about the market access and reimbursement landscape in Canada? What changes can we expect at the Canadian Agency for Drugs and Technologies in Health...

Top 10 HEOR trends – A detailed look at ISPOR’s 2024–2025 topics

Specialists from across Mtech Access to look at each of ISPOR’s top 10 HEOR trends for 2024–2025. Jump in as the Mtech Access experts give their hot take on each...

Rare disease market access – Launching orphan drugs in secondary markets: the Nordic and MENA regions

Join us live at 1.00pm (GMT)/2.00pm (CET)/8.00am (EST) on Thursday 29th February, to explore rare disease market access challenges and learn more about these high potential markets.

The pitfalls of cutting costs on systematic literature reviews: 11 common issues to avoid

Embarking on a systematic literature review is a critical step in evidence synthesis, providing a foundation for robust decision-making in the healthcare landscape. As with most things, there are ways...

How does funding flow in NHSE Regions? – Live Webinar

On Friday 23rd February at 2.00pm, we will sit down with guest speaker Richard Smale (Interim Director of System Co-ordination, NHS England [NHSE] – South West) for an all-encompassing discussion...

Digital options to enhance your local market access materials

How can a digital approach enhance local customer communication, particularly when tools are adapted from existing global materials? What are the options? How can we build in efficiencies whilst meeting...

So, what is happening with specialised commissioning in the NHS?

Specialised commissioning continues to be an issue of significance and uncertainty for both the NHS and industry. What do the latest reports of regional push back on the plans for...

Mtech Access certified as a NICE META tool facilitating organisation

Mtech Access are now a certified NICE META Tool facilitating organisation, with three experts having passed the NICE assessment